Group 1 - Jilin Aodong (000623) participated in an investor relations event to enhance communication between investors and the company, showcasing its business scope which includes traditional Chinese medicine, chemical drugs, and health products [1] - The company has 628 production approval numbers, with 315 for traditional Chinese medicine, and aims to leverage its brand and product quality to enhance market value and sales of key products [1] - Jilin Aodong plans to cultivate multiple core products with over 100 million yuan in sales and accelerate the development of strategic products with a market potential of 10 billion yuan [1] Group 2 - The Yanbian Pharmaceutical project has completed several production facilities, which passed GMP compliance checks and are now contributing to revenue [2] - In 2024, the health business is expected to generate 212 million yuan in sales, accounting for 8.13% of total revenue, with over 200 health products produced and sold [2] - The company has 22 registered health food certificates and 85 filing certificates, with 43 products generating over 1 million yuan in sales [2] Group 3 - Jilin Aodong is enhancing brand awareness through diverse marketing strategies, including e-commerce and social media platforms like Douyin [3] - The company is focusing on the core value of traditional Chinese medicinal materials and aims to develop high-value projects through research and innovation [3] - The health product development system is driven by consumer health trends, emphasizing research and development of functional health products [3] Group 4 - The company is investing in core quality long-term equity securities and related pharmaceutical companies, collaborating with various funds to invest in biopharmaceuticals and internet healthcare [4] - Jilin Aodong aims to strengthen its research capabilities through indirect investments in distinctive and competitive biopharmaceutical projects [4] - The company is optimizing its financial asset allocation to create a positive cycle of financial capital supporting real industry growth [4]

Group 1: Company Overview and Business Focus - Jilin Aodong Pharmaceutical Group Co., Ltd. focuses on the pharmaceutical industry, including traditional Chinese medicine, chemical drugs, and health products [2][3] - The company has 628 production approval numbers, with 315 for traditional Chinese medicine and 525 for traditional Chinese medicine formula granules [3] - The company aims to enhance its core products, such as Anshen Bnnao Liquid and Xiaoer Chaigui Oral Liquid, to achieve high-quality development and cultivate multiple billion-yuan core products [3] Group 2: Financial Performance and Shareholder Returns - The company has implemented a cash dividend policy for 17 consecutive years, with a total cash dividend of 4.505 billion yuan [3] - A three-year shareholder return plan (2024-2026) aims to increase dividend frequency and optimize the dividend rhythm, ensuring stable and reasonable returns for shareholders [3] Group 3: Health Products and Market Strategy - In 2024, the health business generated sales revenue of 212.13 million yuan, accounting for 8.13% of total revenue [5] - The company produces over 200 health products, with 43 single products generating sales revenue exceeding one million yuan [5] - The company is enhancing its marketing strategies through e-commerce channels, including short videos and live broadcasts, to boost brand awareness and sales [5] Group 4: Research and Development Initiatives - The company is focusing on traditional Chinese medicine classic formulas and formula granules, with production facilities for these products already operational [4] - The company is committed to developing high-value projects using traditional Chinese medicinal materials, such as ginseng and deer antler, to meet the growing health consumption trends [5] Group 5: Investment Strategy - The company is shifting its investment focus towards the pharmaceutical industry chain and innovative pharmaceutical enterprises, including biotechnology companies [5] - Collaborations with various funds aim to invest in distinctive and competitive biopharmaceutical projects, enhancing the company's research capabilities [5]

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. has announced its 2024 annual cash dividend plan, which includes a total cash distribution of 351,714,476.10 yuan, with a dividend of 3.00 yuan per 10 shares for eligible shareholders [2][3][7]. Summary by Sections Dividend Distribution Plan - The 2024 annual cash dividend plan was approved at the shareholders' meeting on May 23, 2025, with a total share capital of 1,195,895,387 shares, excluding 23,513,800 shares held in the company's repurchase account, resulting in a base of 1,172,381,587 shares for the cash dividend distribution [3][4]. - The cash dividend distribution will be 3.00 yuan per 10 shares (before tax), with a total cash distribution amounting to 351,714,476.10 yuan [3][7]. Dividend Payment Details - The cash dividend will be distributed on July 9, 2025, with the record date set for July 8, 2025 [8][9]. - The cash dividends will be directly credited to the shareholders' accounts through their securities companies [9][10]. Taxation Information - Different tax rates will apply based on the type of shares held, with specific provisions for Hong Kong investors and domestic investors [8]. - The company will not withhold individual income tax at the time of distribution; instead, it will be calculated based on the holding period when shares are sold [8]. Adjustments and Calculations - The actual cash dividend amount is calculated based on the total shares eligible for distribution multiplied by the distribution ratio, resulting in a per-share cash dividend of approximately 0.2941013 yuan after the distribution [2][11]. - The ex-dividend price will be adjusted accordingly, calculated as the closing price on the record date minus the per-share cash dividend [11].

证券代码：000623 证券简称：吉林敖东 公告编号：2025-034 吉林敖东药业集团股份有限公司 2024年度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 公司2024年度利润分配方案已获公司于2025年5月23日召开的2024年度股东 大会审议通过，详见公司于2025年5月24日在《证券时报》《上海证券报》《中 国证券报》《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）披露的《2024 年度股东大会决议公告》（公告编号：2025-029）。现将分红派息事宜公告如下： 一、股东大会审议通过利润分配方案情况 1．公司于 2025 年 5 月 23 日召开的 2024 年度股东大会审议通过了公司 2024 年度现金分红方案：以 2025 年 3 月 31 日的总股本 1,195,895,387 股扣除公司股 票回购专用证券账户上的股份 23,513,800 股后的 1,172,381,587 股为基数，向 全体股东每 10 股派发现金股利 3.00 元（含税），预计分派现金 351,714,476.1 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 吉林敖东药业集团股份有限公司（以下简称"公司"）接到股东敦化市金诚 实业有限责任公司（以下简称"金诚公司"）函告，获悉金诚公司所持有公司的 部分股份办理质押及解除质押手续，具体事项如下： （一）股东股份质押 1、股东股份质押基本情况 | 股东名称 | 是否为控股 股东或第一 | 本次质押 | 占其所持 | 占公司总 | 是否 | 是否为 | | | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 | 数量(万 | 股份比例 | 股本比例 | 为限 | 补充质 | 质押起始日 | 质押到期日 | 质权人 | 用途 | | | 一致行动人 | 股) | | | 售股 | 押 | | | | | | 敦化市金 诚实业有 | | | | | | | 2025 年 6 月 | 质押期限至 其办理解除 | 上海海通 证券资产 | 经营 | | | 是 | 1,093.75 | 3 ...

Group 1 - Banqiao Qiancheng signed a significant contract with Mango Film and Television for a total amount of 372 million yuan, accounting for 50.65% of the company's audited main business income for 2024 [1] - The contract allows Mango Film and Television to use the new media and traditional media broadcasting rights for related film and television works globally, positively impacting Banqiao Qiancheng's financial status and operating performance in 2025 and beyond [1] - Jingwei Huikai plans to sell its wholly-owned subsidiary Changsha Yushun for 112 million yuan, which will no longer be included in the consolidated financial statements after the transaction [1] Group 2 - Minsheng Health's subsidiary received a patent for a strain of lactic acid bacteria that significantly improves sarcopenic obesity, although it has not yet been applied to the company's products [2] - Dafu Technology intends to transfer 27% of its subsidiary Shenzhen Peitian Intelligent Manufacturing Equipment Co., Ltd. for 192 million yuan, maintaining a controlling stake post-transaction [3] - Feilong Co. received orders for high-power electronic water pumps for data centers from a well-known global power electronics provider [4] Group 3 - Yatai Co. was selected as a supplier for a foreign brand's EPB project, with a total sales amount of approximately 680 million yuan over a five-year lifecycle [5] - Gansu Energy's 1 million kilowatt wind-solar integrated project has received approval, representing over 10% of the company's installed capacity by the end of 2024 [6] - Jilin Aodong's subsidiary received approval for a drug supplement application for "Tang Le Capsule," used to treat symptoms related to diabetes [7] Group 4 - Shanshui Technology plans to invest 6 billion yuan in a new chemical materials project, expected to generate an annual output value of 8 billion yuan upon completion [8] - Dazhu CNC's H-share issuance application has been accepted by the China Securities Regulatory Commission [9] - Zhujiang Beer announced the resignation of its chairman due to retirement age, with a new chairman elected on the same day [10] Group 5 - Longkun Technology won a bid for a waste collection service project worth 21.57 million yuan, with a service period of one year [11] - Zhongnan Culture plans to provide financial support of up to 20 million yuan to its subsidiary for daily operational needs [12] - Shangfeng Cement's investment in a company applying for an IPO on the Sci-Tech Innovation Board has been accepted [13] Group 6 - Chuanheng Co. received a patent for a system and method for harmless treatment of phosphorus tailings [14] - Toukeng Life's seven medical device registration applications have been accepted, covering various diagnostic fields [15] - Xingqi Eye Medicine's clinical trial for a new eye gel has commenced with the first subject enrolled [16] Group 7 - Jiebang Technology plans to provide financial support of up to 60 million yuan to its subsidiary for operational needs [17] - Shenzhen Airport reported a passenger throughput of 5.54 million in May, a year-on-year increase of 15.67% [18] - Wan'an Technology received a cash dividend of 30 million yuan from its wholly-owned subsidiary [19] Group 8 - Jiuchuan Bio received a medical device registration certificate for a cystatin C assay kit [20] - Hongqiang Co. obtained a safety production license for its subsidiary, marking the official production of a new project [21] - Xiangtan Electric plans to issue convertible bonds totaling 487 million yuan [22] Group 9 - Guangwei Composite signed a supplementary material procurement contract worth 658 million yuan [23] - Jichuan Pharmaceutical announced a comprehensive tender offer starting June 18, with a price of 26.93 yuan per share [24] - Aerospace Rainbow plans to distribute cash dividends of 0.60 yuan per share [25] Group 10 - Industrial Bank plans to distribute cash dividends of 1.06 yuan per share, totaling 22.433 billion yuan [26] - China Automotive Research will repurchase and cancel 230,800 restricted shares due to the retirement of original incentive objects [27] - Annie Co. announced abnormal stock trading fluctuations but confirmed no significant changes in its operations [28] Group 11 - Giant Network confirmed no undisclosed significant matters following abnormal stock trading fluctuations [29]

证券代码：000623 证券简称：吉林敖东 公告编号：2025-032 吉林敖东药业集团股份有限公司 关于控股子公司获得药品补充申请批准通知书 的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉 林敖东药业集团延吉股份有限公司（以下简称"延吉药业"）收到国家药品监督 管理局下发的"糖乐胶囊"的《药品补充申请批准通知书》。现就相关情况公告 如下： 一、《药品补充申请批准通知书》的主要内容 1．糖乐胶囊 药品通用名称：糖乐胶囊 剂型：胶囊剂 规格：每粒装0.3g 注册分类：中药 受理号：CYZB2500952 通知书编号：2025B02585 原药品批准文号：国药准字Z20025227 上市许可持有人名称：吉林敖东药业集团延吉股份有限公司 上市许可持有人地址：吉林省延吉市高新技术开发区长白路389号 生产企业名称：吉林省德商药业股份有限公司 生产企业地址：吉林省辉南县经济开发区北一街 申请内容：其他：变更糖乐胶囊（国药准字Z20025227）的上市许可持有人， 主体由吉林省德商药 ...

吉林敖东药业集团股份有限公司（以下简称"公司"）于 2016 年 7 月 15 日 召开的 2016 年第一次临时股东大会审议通过了《<吉林敖东药业集团股份有限公 司员工持股计划（草案）>及其摘要》的议案，具体内容详见 2016 年 6 月 30 日、 2016 年 7 月 16 日在《中国证券报》《上海证券报》《证券时报》《证券日报》 及巨潮资讯网（http://www.cninfo.com.cn）披露的相关公告。 鉴于公司第一期员工持股计划存续期将于 2025 年 12 月 8 日届满，根据中国 证券监督管理委员会《关于上市公司实施员工持股计划试点的指导意见》、深圳 证券交易所《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》相关规定，上市公司应当在员工持股计划届满前六个月公告即将到期的 员工持股计划所持有的股票数量及占公司股本总额的比例，现将相关情况公告如 下： 一、本次员工持股计划存续期内的持股情况 1.公司于 2016 年 7 月 15 日召开的 2016 年第一次临时股东大会审议通过了 《<吉林敖东药业集团股份有限公司员工持股计划（草案）>及其摘要》的议案， 具体内容详见 ...

Core Viewpoint - Jilin Aodong (000623) announced that its subsidiary Yanbian Pharmaceutical has obtained 25 listings for traditional Chinese medicine formula granules, which will positively impact the company's expansion in this business segment and enhance its core competitiveness [1] Group 1: Company Developments - Yanbian Pharmaceutical has received a total of 525 listing certificates for traditional Chinese medicine formula granules as of the announcement date [1] - The newly obtained products include Jiu Bi Ying, American ginseng, Huoxiang, and fried rice sprouts [1] Group 2: Market Impact - The sales performance of the newly listed products may be influenced by changes in the market environment, indicating potential uncertainties [1] - The short-term impact on the company's overall performance is not expected to be significant [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉 林敖东延边药业股份有限公司（以下简称"延边药业"）获得25个《中药配方颗 粒上市备案凭证》，现就相关情况公告如下： 证券代码：000623 证券简称：吉林敖东 公告编号：2025-030 吉林敖东药业集团股份有限公司 关于控股子公司获得中药配方颗粒上市备案凭证 的自愿性信息披露公告 一、《中药配方颗粒上市备案凭证》的主要内容 根据《中华人民共和国药品管理法》《中华人民共和国药品管理法实施条例》 等法律和法规的规定，对延边药业的以下产品予以备案： | 序号 | 名称 | 备案号 | | --- | --- | --- | | 1 | 救必应配方颗粒 | 上市备字2225000023000 | | 2 | 西洋参配方颗粒 | 上市备字2225000036000 | | 3 | 藿香配方颗粒 | 上市备字2225000066000 | | 4 | 炒稻芽配方颗粒 | 上市备字2225000067000 | | 5 | 六月雪（六月雪）配方颗粒 | 上市 ...